Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bio-Rad Laboratories (BIO)
NYSE:BIO
Holding BIO?
Track your performance easily
BIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$262.12 - $387.99
Previous Close$327.47
Volume691.29K
Average Volume (3M)200.46K
Market Cap
$9.18B
Enterprise Value$8.94B
Total Cash (Recent Filing)$1.62B
Total Debt (Recent Filing)$1.39B
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Feb 13, 2025EPS Estimate
$2.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.33
Shares Outstanding27,996,765
10 Day Avg. Volume5,055,520
30 Day Avg. Volume200,463
Standard Deviation0.10
R-Squared0.20
Alpha-0.00691
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.22
Price to Sales (P/S)3.55
Price to Cash Flow (P/CF)14.00
P/FCF Ratio17.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.47
Enterprise Value/Gross Profit6.27
Enterprise Value/Ebitda-10.61
Forecast
1Y Price Target
$399.20Price Target Upside21.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bio-Rad Laboratories News
PremiumCompany Announcements
Bio-Rad Laboratories Reports Q3 2024 Earnings Growth
PremiumPre-Earnings
Is BIO a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Capital AllocationThe potential sale of BIO's stake in Sartorius is seen as a highly sought after asset, which may capture a premium and provide significant capital for mergers and acquisitions.
Investment SuccessBIO's enviable stake in Sartorius highlights its significant investment success, representing a substantial portion of its enterprise value.
Shareholder ValueMonetizing the Sartorius stake could add significant firepower for BIO to accelerate share buybacks, potentially reducing existing float by a large margin and creating further value for shareholders.
Bears Say
Acquisition ChallengesHistoric aspirations for BIO to acquire all of Sartorius are now financially impossible due to massive dilution concerns.
Management And StrategyManagement needs to address questions around CEO succession, plans for Sartorius, capital allocation, and set new long-term growth/margin targets before the relative discount will contract.
Valuation And Ownership StructureBIO's relative valuation discount has only widened, suggesting factors like family ownership and dual-class structure may be outweighing the fundamental narrative.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BIO FAQ
What was Bio-Rad Laboratories’s price range in the past 12 months?
Bio-Rad Laboratories lowest stock price was $262.12 and its highest was $387.99 in the past 12 months.
What is Bio-Rad Laboratories’s market cap?
Currently, no data Available
When is Bio-Rad Laboratories’s upcoming earnings report date?
Bio-Rad Laboratories’s upcoming earnings report date is Feb 13, 2025 which is in 52 days.
How were Bio-Rad Laboratories’s earnings last quarter?
Bio-Rad Laboratories released its earnings results on Oct 30, 2024. The company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.157 by $0.853.
Is Bio-Rad Laboratories overvalued?
According to Wall Street analysts Bio-Rad Laboratories’s price is currently Undervalued.
Does Bio-Rad Laboratories pay dividends?
Bio-Rad Laboratories does not currently pay dividends.
What is Bio-Rad Laboratories’s EPS estimate?
Bio-Rad Laboratories’s EPS estimate is $2.87.
How many shares outstanding does Bio-Rad Laboratories have?
Bio-Rad Laboratories has 22,921,856 shares outstanding.
What happened to Bio-Rad Laboratories’s price movement after its last earnings report?
Bio-Rad Laboratories reported an EPS of $2.01 in its last earnings report, beating expectations of $1.157. Following the earnings report the stock price went up 8.352%.
Which hedge fund is a major shareholder of Bio-Rad Laboratories?
Among the largest hedge funds holding Bio-Rad Laboratories’s share is First Eagle Investment Management LLC. It holds Bio-Rad Laboratories’s shares valued at 239M.
---
Bio-Rad Laboratories Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$399.20 (21.90% Upside)
$399.20 (21.90% Upside)
Blogger Sentiment
Bearish
BIO Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 371.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.21%
12-Months-Change
Fundamentals
Return on Equity
-9.79%
Trailing 12-Months
Asset Growth
-10.86%
Trailing 12-Months
Company Description
Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the following segments: Life Sciences and Clinical Diagnostics. The Life Science segment develops, manufactures and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialize in quality controls that serve clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
---
BIO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a mix of positive developments, such as strong performance in Clinical Diagnostics and improved gross margins, alongside challenges in the Life Science segment and geographic markets like Asia Pacific. Operational efficiencies and cost management initiatives have been beneficial, but headwinds in certain market segments persist.Read More>---
BIO Net sales Breakdown
55.75% Clinical Diagnostics
44.11% Life Science
0.13% Other
---
BIO Stock 12 Month Forecast
Average Price Target
$399.20
▲(21.90% Upside)
Technical Analysis
Best Analysts Covering BIO
1 Year
1 Year Success Rate
8/17 ratings generated profit
1 Year Average Return
+7.66%
reiterated a buy rating 2 months ago
Copying Dan Leonard's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +7.66% per trade.
---